Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Misses on Revenue, Stock Down 24.26%

Aurinia Pharmaceuticals reported a loss of $0.25 per share, which was slightly better than expected. However, the lack of revenue information and no guidance update contributed to a significant drop in the stock price by over 24%. Investors may be concerned about the company's future performance given the absence of detailed insights from management.